XBiotech Inc. Form SC 13G/A February 14, 2017

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. 1)¹

XBIOTECH INC. (Name of Issuer)

Common Shares, no par value (Title of Class of Securities)

98400H102 (CUSIP Number)

December 31, 2016 (Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

[_] Rule 13d-1(b)

[] Rule 13d-1(c)

[x] Rule 13d-1(d)

Edgar Filing: XBiotech Inc. - Form SC 13G/A

¹The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the *Notes*).

SCHEDULE 13G

CUSIP No. 98400H102

1	Names of Reporting Persons John Simard		
	Check the appropriate box if		
	a member of a Group (see		
2	instructions)		
	(a) []		
	(b) []		
3	Sec Use Only		
	Citizenship or Place of		
4	Organization		
	Canada		
Number of Shares 5 ⁵ 7,493,267 ⁽¹⁾			
Shares	5 7,493,267 ⁽¹⁾		
Beneficia	ally Shared Voting Power		
Owned b	y ⁰ N/A		
Each	-Sole Dispositive Power		
Reportin	g 7 <mark>50le Dispositive Power</mark> 7,493,267 ⁽¹⁾		
Person	Shared Dispositive Power		
With:	_		

8_{N/A}

9	Aggregate Amount Beneficially Owned by Each Reporting Person 7,493,267 ⁽¹⁾
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) []
11	Percent of class represented by amount in row (9) 22.2% ⁽²⁾
12	Type of Reporting Person (See Instructions) IN

(1) These figures include shares of common stock underlying stock options held by the Reporting Person, including options which are immediately exercisable within 60 days of December 31, 2016.

(2) The percentage is calculated based upon 32,483,265 shares outstanding as of December 31, 2016.

Page 2 of 5

Edgar Filing: XBiotech Inc. - Form SC 13G/A

Item 1. **(a)** Name of Issuer: XBiotech Inc. **(b)** Address of Issuer's Principal Executive Offices: 8201 E. Riverside Dr. Bldg. 4, Ste. 100 Austin, TX 78744 Item 2. Name of Person Filing: **(a)** John Simard **(b)** Address of Principal Business Office or, if None, Residence: 8201 E. Riverside Dr. Bldg. 4, Ste. 100 Austin, TX 78744 (c) **Citizenship:** Canada **Title and Class of Securities:** (**d**)

(e)

CUSIP No.:

98400H102

Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

Not Applicable

Item 4. Ownership

As of December 31, 2016

(a) Amount Beneficially Owned:

7,493,267⁽¹⁾ shares

(b)

Percent of Class:

 $22.2\%^{(2)}$

(c)Number of shares as to which such person has:

Page 3 of 5

(i) Sole power to vote or to direct the vote:				
7,493,267 ⁽¹⁾ shares	5			
	(ii)	Shared power to vote or to direct the vote:		
Not Applicable				
	(iii) Sole j	power to dispose or to direct the disposition of:		
7,493,267 ⁽¹⁾ shares				
	(iv) Shared	power to dispose or to direct the disposition of:		
Not Applicable				
(1) These figures in options which a	nclude shares of common stoc are immediately exercisable w	k underlying stock options held by the Reporting Person, including ithin 60 days of December 31, 2016.		
(2) The p	ercentage is calculated based	upon 32,483,265 shares outstanding as of December 31, 2016.		
	Item 5.	Ownership of Five Percent or Less of a Class.		
	e 1	that as of the date hereof the reporting person has ceased to be the e class of securities, check the following [].		
Item	6. Ownership o	f more than Five Percent on Behalf of Another Person.		
Not Applicable				

7

	ĽΟ	
	Identification and classification parent holding company or compan	on of the subsidiary which acquired the security being reported on by the ontrol person.
Not Aj	pplicable	
	Item 8.	Identification and classification of members of the group.
Not Aj	pplicable	
	Item 9.	Notice of Dissolution of Group.
Not Aj	pplicable	
	Item 1	0. Certifications.
Not Aj	pplicable	

Page 4 of 5

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: February 14, 2017

<u>/s/ John Simard</u>

John Simard/President & CEO, XBiotech Inc.

Page 5 of 5